Optimizing Market Access and the new European HTA Regulation

Join us for this Science for Lunch event on how to optimize Pricing & Reimbursement strategies and the impact of early market access interventions hosted by ProPharma Group.

Securing timely market access and establishing fair pricing and reimbursement models are pivotal for pharmaceutical companies’ success. ProPharma will in this presentation navigate market access challenges, address payer concerns, and adapt to the new EU HTA Regulation through proactive strategies.

Three Takeaways

• Early and proactive market access planning and interventions foster faster patient access and increase the commercial success of pharmaceutical companies.
• The new European HTA Regulation (HTAR) standardizes clinical assessments across Member States, by requiring a Joint Clinical Assessment (JCA) dossier during the market authorization process, which will revolutionize the evaluation of new medicines and health technologies in Europe.
• Proactive engagement with regulatory processes ensures smoother navigation of hurdles, convincingly demonstrates value propositions, and speeds up patient access to groundbreaking treatments.

Speakers

Anders Ersson, Director Business Development; and Katarina Ericson, Associate Director Pricing & Reimbursement, at ProPharma Group.

About ProPharma

ProPharma is a global leader in life sciences, specializing in regulatory, clinical research, quality, compliance, pharmacovigilance, medical information and market access. We partner with biotech, pharmaceutical, and medical device companies to bring therapies to market and support the products’ lifecycle.